Group 1 - The article does not contain relevant content regarding company or industry insights [1]

Core Insights - The company provided a business update regarding its REYOBIQ clinical program and CNSide U.S. commercialization [2][3] Company Developments - The latest corporate presentation was filed with the SEC in an 8-K filing and is available on the company's website [3] - The conference call included participation from the CEO and CFO, indicating a focus on future performance and operational results [3] Communication and Transparency - The company emphasized the availability of its press release and corporate presentation on its website for investor access [2][3]

Summary of Plus Therapeutics Conference Call - January 22, 2026 Company Overview - **Company**: Plus Therapeutics (NasdaqCM:PSTV) - **Focus**: Development of CNSide and RIOVA clinical programs Key Points Financial Update - **Recent Offering**: Completed a $15 million oversubscribed financial offering on January 14, 2026, which extends the company's runway through 2027 [4] - **Use of Funds**: Funds will be used to expand CNSide investments to achieve break-even by 2027 and to complete ongoing phase II RIOVA clinical trials [4] RIOVA Clinical Program - **FDA Interaction**: Positive feedback from a Type B meeting with the FDA in November 2025, which will expedite RIOVA clinical development timelines [5] - **Trial Design**: Agreement on a randomized pivotal trial design focusing on neurologic condition improvements, patient-reported outcomes, and overall survival as key endpoints [6] - **2026 Goals**: Aim to identify optimal RIOVA dosing regimes and expand into a 12-patient dose expansion arm for additional safety and efficacy data [7] - **Enrollment Progress**: On track to complete phase II enrollment for recurrent glioblastoma (GBM) with data expected in Q4 2026 [7] CNSide Commercialization - **Licensure**: Achieved state licensure in 49 of 50 U.S. states, with agreements covering 67 million lives through partnerships with UnitedHealthcare and Humana [8] - **2026 Focus**: Targeting over 150 million covered lives through additional payer agreements, obtaining Medicare and Medicaid coverage, and ramping up testing utilization to reestablish previous commercial run rates of 1,250 tests per year [8] - **Physician Engagement**: Goal to establish a base of 50 unique ordering physicians, with a long-term target of reaching 200 [28] Operational Insights - **Testing Goals**: Aiming for 1,250 tests per year as a minimum goal, which is expected to cover only a quarter of the path to profitability; a target of 5,000 tests is needed for full profitability [31] - **Cost Efficiency**: Significant opportunities for automation and cost reductions have been identified since acquiring testing assets from the previous company [32] Strategic Outlook - **Market Positioning**: Emphasis on improving diagnostic capabilities with CNSide and bringing the RIOVA drug to market to address unmet medical needs in CNS cancers [35] - **Future Announcements**: Management is optimistic about upcoming announcements that could positively impact stock performance, with no immediate plans for a reverse stock split [19] Risk Factors - **Forward-Looking Statements**: The company has cautioned that actual results may differ from expectations due to various risks outlined in their SEC filings [3] Additional Considerations - **Payer Dynamics**: The company is working on obtaining PLA and DEX Z-Codes for Medicare and Medicaid coverage, which are crucial for expanding market access [26] - **Patient Demographics**: Noted that the demographic for CNSide testing skews younger, with a 60/40 split between private payers and Medicare [27] This summary encapsulates the critical updates and strategic direction of Plus Therapeutics as discussed in the conference call, highlighting both opportunities and challenges ahead.

Corporate Update January 2026 Power and precision in cancer radiotherapeutics NASDAQ: PSTV Cautionary Note Regarding Forward Looking Statements This presentation contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this presentation other than statements of historical fact are forward-looking statements. These forward-looking statements m ...

Core Insights - Plus Therapeutics, Inc. is advancing its clinical-stage pharmaceutical initiatives focused on targeted radiotherapeutics for central nervous system (CNS) cancers, with significant progress in both clinical trials and diagnostic platform technologies [2][8] Corporate Highlights - The company completed a restructuring of a $15 million equity financing, simplifying its capital structure [6] - Plus Therapeutics received an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a previously awarded $17.6 million grant [6] - The company appointed Kyle Guse, an industry veteran with 30 years of experience, to its Board of Directors [6] - Plus Therapeutics presented updated interim data on its lead compound REYOBIQ™ at a conference, highlighting its safety and clinical benefits for patients with leptomeningeal metastases [6] Clinical Development - The REYOBIQ™ clinical trials are demonstrating favorable safety and efficacy signals, which are facilitating active enrollment in the dose optimization trial [2][4] - The company initiated the ReSPECT-LM dose optimization trial for REYOBIQ, treating the first two patients to evaluate multiple-dose regimens [6] - The U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for REYOBIQ for pediatric patients with specific high-grade gliomas, supported by a $3 million grant from the Department of Defense [6] CNSide CSF Assay Platform - The CNSide CSF assay platform is set to launch in Texas, focusing initially on National Cancer Institute Designated Cancer Centers [10] - The total addressable market for the CNSide CSF Tumor Cell Enumeration (TCE) test is estimated to be $6 billion in the U.S., with plans to add three additional CNS assays [10] - The company aims to expand CNSide testing services regionally over the next 12 months [2][10] Financial Performance - As of June 30, 2025, the company reported cash and investments of $6.9 million, an increase from $3.6 million at the end of 2024 [10] - Grant revenue for Q2 2025 was $1.4 million, compared to $1.3 million in the same quarter of 2024 [10] - The total operating loss for Q2 2025 was $1.5 million, a decrease from $3.7 million in Q2 2024, attributed to improved operational cost control [10] - The company reported a net income of $5.2 million for Q2 2025, a significant turnaround from a net loss of $2.9 million in the same quarter the previous year [10]

Market Overview - U.S. stocks showed mixed performance with the Dow Jones index falling approximately 0.2% to 43,011.70, while the NASDAQ rose by 0.20% to 19,953.27 and the S&P 500 increased by 0.02% to 6,093.14 [1] - Information technology shares experienced a notable increase of 0.8%, while real estate stocks declined by 1.3% [1] Commodities - Crude oil prices rose by 2.5% to $65.99, gold increased by 0.3% to $3,343.80, silver was up 1% to $36.070, and copper rose by 0.7% to $4.9605 [5] European Markets - European shares were generally lower, with the eurozone's STOXX 600 falling by 0.74%, Spain's IBEX 35 Index down 1.59%, London's FTSE 100 down 0.46%, Germany's DAX 40 down 0.61%, and France's CAC 40 slipping by 0.76% [6] Asian Markets - Asian markets closed higher, with Japan's Nikkei gaining 0.39%, Hong Kong's Hang Seng Index up 1.23%, China's Shanghai Composite rising 1.04%, and India's BSE Sensex increasing by 0.85% [7] Company News - Plus Therapeutics, Inc. saw its shares surge by 59% to $0.2968 following FDA clearance for its investigational new drug application for REYOBIQ [9] - QuantumScape Corporation's shares rose by 36% to $5.88 after achieving a key milestone in integrating its advanced Cobra separator process [9] - SeaStar Medical Holding Corporation's shares increased by 49% to $0.5362 due to strategic actions for Nasdaq compliance [9] - Lifeward Ltd. experienced a drop of 38% to $0.6015 after announcing a public offering of 4 million shares at $0.65 per share [9] - Torrid Holdings Inc. shares fell by 37% to $3.1900 following the pricing of a secondary offering of 10 million shares at $3.50 per share [9] - Allot Ltd. shares decreased by 17% to $8.01 after announcing a public offering of 5 million shares at $8.00 per share [9] Economic Indicators - Sales of new single-family homes in the U.S. decreased by 13.7% to an annualized rate of 623,000 units in May [11] - U.S. building permits fell by 2% to an annualized rate of 1.394 million in May [11] - The volume of mortgage applications in the U.S. increased by 1.1% from the previous week [11] - U.S. crude oil inventories declined by 5.836 million barrels, significantly exceeding market estimates of a 0.75 million barrel decrease [11]